| HOME >> BIOLOGY >> TECHNOLOGY |
DILUTED ADJUSTED INCOME PER COMMON
SHARE $1.18 $0.92
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING 68,118 66,931
WEIGHTED AVERAGE NUMBER OF COMMON
SHARES OUTSTANDING-ASSUMING DILUTION 78,920 79,030
Notes to Reconciliation of GAAP Net Income to Adjusted Net Income
(1) To exclude the on-going amortization of acquired intangible assets ($24.0 million in 2008; $22.3 million in 2007), accelerated depreciation related to the CIMA LABS restructuring ($1.6 million in 2008), accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($2.9 million in 2008), and the write-off of purchase commitments in excess of estimated requirements ($26.0 million in 2008).
(2) In 2008, to exclude accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility. In 2007, to exclude the recognition of a milestone related to the FDA's acceptance of our NDA filing for TREANDA (bendamustine HCl).
(3) To exclude charges related to the estimated termination payments due to Takeda Pharmaceuticals North America, Inc.
(4) In 2008, to exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. In 2007, to exclude the reserve established for the minimum liability related to the potential settlement of the investigations by the U.S. Attorney's Office.
(5) To exclude the forgiveness of a mortgage loan by the Pennsylvania Industrial Development Board ("PIDA").
(6) To exclude the accrued interest related to the settlement reached with the U.S. Attorney's Office.
(7) To exclude costs related to the CIMA LABS restructuring announced in January 2008.
(8) To reflect the tax effect of pre-tax adjustments at the applicable
tax rates and certain other
'/>"/>
| SOURCE Cephalon, Inc. Copyright©2008 PR Newswire. All rights reserved |